December 16, 2020
From Kyprolis to PROTACs - Insights with Amgen's Ray Deshaies
Recorded live December 15, 2020
In this webinar, Dr. Ray Deshaies (SVP Global Research, Amgen) shared stories on the discovery of cancer drug Kyprolis, the inspiration for PROTAC, and the new drug discovery modality of "induced proximity", followed by a demo of CDD's new BioHarmony semantic drug database.
Webinar Summary
In 2003, then Caltech Professor Raymond Deshaies co-founded Proteolix to develop a proteasome-inhibiting compound that would later lead to the billion-dollar cancer drug carfilzomib/Kyprolis®. The company was subsequently acquired by Onyx and then Amgen.
In this webinar, Dr. Deshaies (now SVP of Global Research at Amgen) will share with Dr. Barry Bunin (CEO, Collaborative Drug Discovery) the story behind the discovery of Kyprolis, as well as discuss the latest developments in areas related to PROTACs and COVID-19 biology. It will be a rare opportunity to get direct insights from a high-profile drug discovery pioneer that you don't want to miss.
In addition, this will be the first chance for a sneak peak of CDD's BioHarmony - a modern semantic drug data store that offers real-time data streams on thousands of drugs, including Kyprolis.
Featuring these leading scientists...
Raymond Deshaies, Ph.D.
Senior Vice President, Amgen
Dr. Deshaies is Senior Vice President, Global Research at Amgen. Prior to that he served as a professor at the California Institute of Technology (Caltech) and an executive officer in Caltech's Division of Biology and Biological Engineering. He was also an investigator at the Howard Hughes Medical Institute.
In addition to his academic work, Deshaies co-founded Proteolix in 2003. In 2011, he co-founded Cleave Biosciences.
Deshaies holds a bachelor's degree in biochemistry from Cornell University and a Ph.D. in biochemistry from the University of California, Berkeley. He is also a member of the National Academy of Sciences.
Barry Bunin, Ph.D.
Founder & CEO, Collaborative Drug Discovery
Dr. Bunin founded CDD in 2004 to pioneer CDD Vault, a hosted research data management system. Prior to CDD, he was an Entrepreneur in Residence with Eli Lilly, as well as the founding CEO, President, & CSO of Libraria (now Eidogen-Sertanty).
On the scientific side, Dr. Bunin is an expert in cheminformatics and combinatorial chemistry, and has written two books in those fields. He is also on the patent of Kyprolis, a selective proteasome inhibitor for treating multiple myeloma.
Dr. Bunin received his B.A. from Columbia University and his Ph.D. from UC Berkeley, where he synthesized and tested the initial 1,4-benzodiazepine libraries with Professor Jonathan Ellman